Company to send 12 million doses of COVID-19 vaccine adapted to target Omicron.
Moderna is supplying Canada with 12 million COVID-19 shots specifically designed to target the Omicron variant of COVID-19.
Last year, the Canadian government entered into a supply deal with the company for supply of its COVID vaccine for 2022 and 2023.
The contract does allow for access to new adaptations of the vaccine.
Moderna and Canada have agreed to convert six million doses of the company's COVID vaccine, which targets the original virus, to an Omicron-containing bivalent one.
The country will also purchase an addition 4.5 million doses of the Omicron-targeted shot, and is moving forward with a scheduled delivery of 1.5 million shots of the bivalent vaccine.
While existing COVID-19 inoculations continue to provide protections against hospitalization and death, experts say the effectiveness of the vaccine has decreased as the virus has evolved.
Chief Public Health Officer Dr. Theresa Tam says Health Canada is still reviewing submissions for bivalent vaccines from Moderna and Pfizer.
Public Health Asking for $42-Mill
Fort Erie Increasing Pressure on Niagara Health
Young Offender Arrested in Vape Store Theft
150th Birthday Celebrated at Montebello Park
City Encouraged to Go After Funding
Cost of Renewing Vows Could Rise
GM Investing in St. Catharines
NRP Investigating Fatal Pelham Crash